Among them, 9 papers indicated that KRAS mutations were associated with worse prognosis, 15 failed to demonstrate any statistically significant association between such mutations and prognosis, and, finally, one data set identified an improved survival rate for patents with CRC and KRAS mutations [57]. The gene discussed is KRAS; the disease is colorectal carcinoma.